Details for New Drug Application (NDA): 062595
✉ Email this page to a colleague
NDA 062595 describes NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE, which is a drug marketed by Fougera and Pharmaderm and is included in four NDAs. Additional details are available on the NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE profile page.
The generic ingredient in NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE is neomycin sulfate; triamcinolone acetonide. There are nineteen drug master file entries for this compound. Additional details are available on the neomycin sulfate; triamcinolone acetonide profile page.
The generic ingredient in NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE is neomycin sulfate; triamcinolone acetonide. There are nineteen drug master file entries for this compound. Additional details are available on the neomycin sulfate; triamcinolone acetonide profile page.
Summary for 062595
| Tradename: | NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE |
| Applicant: | Pharmaderm |
| Ingredient: | neomycin sulfate; triamcinolone acetonide |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CREAM;TOPICAL | Strength | EQ 3.5MG BASE/GM;0.1% | ||||
| Approval Date: | Jul 21, 1986 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
